瘦型非酒精性脂肪性肝病的研究进展
DOI: 10.3969/j.issn.1001-5256.2023.12.024
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:张瑜娟负责收集数据,资料分析,撰写论文;周希乔负责拟定写作思路,指导文章并最后定稿。
-
摘要: 非酒精性脂肪性肝病(NAFLD)是目前全球慢性肝病的主要原因,可进展为肝炎、肝纤维化、肝硬化甚至肝细胞癌,虽然肥胖在NAFLD发生中起着关键作用,但越来越多的研究证实NAFLD在瘦型个体中依然存在,且瘦型NAFLD的死亡风险增加、疾病进展加速。因此,瘦型NAFLD也值得仔细评估和随访,但目前有关瘦型NAFLD的病理生理机制仍知之甚少,本文就瘦型NAFLD的病因、诊断、治疗及预后作一综述。Abstract: Nonalcoholic fatty liver disease (NAFLD) is currently the main cause of chronic liver disease worldwide, and it can progress to hepatitis, liver fibrosis, liver cirrhosis, and even hepatocellular carcinoma. Although obesity plays a key role in the development of NAFLD, more and more studies have confirmed that NAFLD still exists in lean individuals, and lean NAFLD is associated with an increased risk of death and accelerated disease progression. Therefore, lean NAFLD also deserves careful evaluation and follow-up; however, we still know little about the pathophysiological mechanism of lean NAFLD. This article reviews the etiology, diagnosis, treatment, and prognosis of lean NAFLD.
-
Key words:
- Nonalcoholic Fatty Liver Disease /
- Somatotypes /
- Diagnosis /
- Therapeutics /
- Risk Factors
-
表 1 瘦型NAFLD发病率总结
Table 1. Summary of incidence rate of lean NAFLD
作者 国家 来源 样本量(例) 瘦型NAFLD 患病率(%) 诊断标准 Zou B等[3] 美国 NHANES数据库 14 365 9.6 超声 Niriella MA等[4] 斯里兰卡 社区人群 2 985 4.0 超声 Zeng J等[5] 中国 社区人群 2 715 5.2 超声 Navarroza AMC 等[6] 菲律宾 医院体检 663 11.9 超声 Weinberg EM等[2] 美国 NAFLD患者 3 386 12.8 超声 Naderian M等[7] 伊朗 社区人群 927 5.93 超声 Younes R等[8] 意大利 NAFLD患者 1 339 14.4 肝组织活检 -
[1] YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7. [2] WEINBERG EM, TRINH HN, FIRPI RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases[J]. Clin Gastroenterol Hepatol, 2021, 19( 5): 996- 1008.e6. DOI: 10.1016/j.cgh.2020.06.066. [3] ZOU B, YEO YH, NGUYEN VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016[J]. J Intern Med, 2020, 288( 1): 139- 151. DOI: 10.1111/joim.13069. [4] NIRIELLA MA, KASTURIRATNE A, PATHMESWARAN A, et al. Lean non-alcoholic fatty liver disease(lean NAFLD): Characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka[J]. Hepatol Int, 2019, 13( 3): 314- 322. DOI: 10.1007/s12072-018-9916-4. [5] ZENG J, YANG RX, SUN C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2020, 26( 15): 1792- 1804. DOI: 10.3748/wjg.v26.i15.1792. [6] NAVARROZA AMC, WONG SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease[J]. Indian J Gastroenterol, 2021, 40( 4): 380- 388. DOI: 10.1007/s12664-021-01184-6. [7] NADERIAN M, KOLAHDOOZAN S, SHARIFI AS, et al. Assessment of lean patients with non-alcoholic fatty liver disease in a middle income country; prevalence and its association with metabolic disorders: A cross-sectional study[J]. Arch Iran Med, 2017, 20( 4): 211- 217. [8] YOUNES R, GOVAERE O, PETTA S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?[J]. Gut, 2022, 71( 2): 382- 390. DOI: 10.1136/gutjnl-2020-322564. [9] SHIDA T, OSHIDA N, SUZUKI H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan[J]. Hepatol Res, 2020, 50( 9): 1032- 1046. DOI: 10.1111/hepr.13543. [10] FENG RN, DU SS, WANG C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J]. World J Gastroenterol, 2014, 20( 47): 17932- 17940. DOI: 10.3748/wjg.v20.i47.17932. [11] BYEON JH, KANG MK, KIM MC. Association of low skeletal muscle mass with the phenotype of lean non-alcoholic fatty liver disease[J]. Healthcare, 2022, 10( 5): 850. DOI: 10.3390/healthcare10050850. [12] ZHANG XX, HE ZY, SI QY, et al. The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2022, 2022: 1- 8. DOI: 10.1155/2022/2229139. [13] ZHU X, HUANG Q, MA S, et al. Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people[J]. Hepatol Int, 2023, 17( 2): 313- 325. DOI: 10.1007/s12072-022-10439-z. [14] CHO Y, CHANG Y, RYU S, et al. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex[J]. Hepatol Commun, 2022, 6( 9): 2238- 2252. DOI: 10.1002/hep4.1975. [15] GAO N, DENG J, WANG J, et al. The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease[J]. Front Med(Lausanne), 2022, 9: 1038475. DOI: 10.3389/fmed.2022.1038475. [16] RASTOGI A, RATH I, VARADARAJAN A, et al. Non-alcoholic fatty liver disease(NAFLD) in lean individuals-Single centre large cohort clinicopathologic and immunophenotypic study[J]. Pathol Res Pract, 2022, 238: 154112. DOI: 10.1016/j.prp.2022.154112. [17] AKYUZ U, YESIL A, YILMAZ Y. Characterization of lean patients with nonalcoholic fatty liver disease: Potential role of high hemoglobin levels[J]. Scand J Gastroenterol, 2015, 50( 3): 341- 346. DOI: 10.3109/00365521.2014.983160. [18] CHEN F, ESMAILI S, ROGERS GB, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation[J]. Hepatology, 2020, 71( 4): 1213- 1227. DOI: 10.1002/hep.30908. [19] HU PF, ZENG X, ZOU ZY, et al. The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: A population-based cross-sectional study[J]. Hepatobiliary Surg Nutr, 2021, 10( 6): 811- 824. DOI: 10.21037/hbsn-20-263. [20] WANG QY, YOU H, OU XJ, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis[J]. Hepatol Int, 2019, 13( 6): 766- 776. DOI: 10.1007/s12072-019-09982-z. [21] LI YF, CHEN YZ, TIAN X, et al. Comparison of clinical characteristics between obese and non-obese patients with nonalcoholic fatty liver disease(NAFLD)[J]. Diabetes Metab Syndr Obes, 2021, 14: 2029- 2039. DOI: 10.2147/dmso.s304634. [22] KWAK JH, JUN DW, LEE SM, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study[J]. Clin Nutr, 2018, 37( 5): 1550- 1557. DOI: 10.1016/j.clnu.2017.08.018. [23] LI CL, GUO PP, OKEKUNLE AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients[J]. J Gastroenterol Hepatol, 2019, 34( 1): 256- 262. DOI: 10.1111/jgh.14360. [24] LIN H, WONG GL, WHATLING C, et al. Association of genetic variations with NAFLD in lean individuals[J]. Liver Int, 2022, 42( 1): 149- 160. DOI: 10.1111/liv.15078. [25] SOOKOIAN S, PIROLA CJ. Genetic predisposition in nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2017, 23( 1): 1- 12. DOI: 10.3350/cmh.2016.0109. [26] IWAKI M, KESSOKU T, OZAKI A, et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2021, 36( 8): 2275- 2284. DOI: 10.1111/jgh.15487. [27] IINO C, ENDO T, IINO K, et al. Reduced equol production and gut microbiota features in men with lean nonalcoholic fatty liver disease[J]. Am J Mens Health, 2022, 16( 4): 15579883221115598. DOI: 10.1177/15579883221115598. [28] YANG YJ, YANG EJ, PARK K, et al. Association between blood mercury levels and non-alcoholic fatty liver disease in non-obese populations: The Korean national environmental health survey(KoNEHS) 2012-2014[J]. Int J Environ Res Public Heath, 2021, 18( 12): 6412. DOI: 10.3390/ijerph18126412. [29] LONG MT, NOUREDDIN M, LIM JK. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review[J]. Gastroenterology, 2022, 163( 3): 764- 774.e1. DOI: 10.1053/j.gastro.2022.06.023. [30] LI K, LI J, CHENG X, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants[J]. Front Endocrinol(Lausanne), 2022, 13: 969783. DOI: 10.3389/fendo.2022.969783. [31] ZOU Y, ZHONG L, HU C, et al. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: A 5-year longitudinal cohort study[J]. Lipids Health Dis, 2021, 20( 1): 28. DOI: 10.1186/s12944-021-01457-1. [32] LI Q, HAN Y, HU H, et al. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults[J]. Front Med(Lausanne), 2022, 9: 995749. DOI: 10.3389/fmed.2022.995749. [33] XIE QY, LU S, KUANG MB, et al. Assessing the longitudinal association between the GGT/HDL-C ratio and NAFLD: A cohort study in a non-obese Chinese population[J]. BMC Gastroenterol, 2022, 22( 1): 500. DOI: 10.1186/s12876-022-02598-y. [34] CHAN WK. Comparison between obese and non-obese nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29( Suppl): S58- S67. DOI: 10.3350/cmh.2022.0350. [35] LI C, GUO P, ZHANG R, et al. Both WHR and FLI as Better Algorithms for Both Lean and Overweight/Obese NAFLD in a Chinese Population. J Clin Gastroenterol. 2019; 53( 6): e253- e260. DOI: 10.1097/MCG.0000000000001089. [36] ZHANG XL, WANG TY, TARGHER G, et al. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease[J]. Diabetes Metab J, 2022, 46( 3): 391- 401. DOI: 10.4093/dmj.2022.0048. [37] WONG VWS, WONG GLH, CHAN RSM, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69( 6): 1349- 1356. DOI: 10.1016/j.jhep.2018.08.011. [38] CIGROVSKI BERKOVIC M, BILIC-CURCIC I, MRZLJAK A, et al. NAFLD and physical exercise: Ready, steady, go![J]. Front Nutr, 2021, 8: 734859. DOI: 10.3389/fnut.2021.734859. [39] ABDELMONEIM D, EL-ADL M, EL-SAYED G, et al. Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats[J]. Fundam Clin Pharmacol, 2021, 35( 2): 379- 388. DOI: 10.1111/fcp.12597. [40] KIM Y, HAN E, LEE JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease[J]. Gut Liver, 2022, 16( 2): 290- 299. DOI: 10.5009/gnl210084. [41] CHEN N, ZHOU JQ, WANG K, et al. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2023, 11( 1): e003066. DOI: 10.1136/bmjdrc-2022-003066. [42] KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects: Characteristics and implications[J]. J Clin Transl Hepatol, 2017, 5( 3): 216- 223. DOI: 10.14218/JCTH.2016.00068. [43] NABI O, LAPIDUS N, BOURSIER J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes(NASH-CO Study)[J]. Hepatology, 2023, 78( 1): 272- 283. DOI: 10.1097/hep.0000000000000329.
本文二维码
表(1)
计量
- 文章访问数: 439
- HTML全文浏览量: 111
- PDF下载量: 107
- 被引次数: 0